First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients.
Medicine (Baltimore)
; 99(48): e23357, 2020 Nov 25.
Article
en En
| MEDLINE
| ID: mdl-33235105
ABSTRACT
INTRODUCTION:
As coronavirus disease 2019 (COVID-19) outbreak globally, repurposing approved drugs is emerging as important therapeutic options. Danoprevir boosted by ritonavir (Ganovo) is a potent hepatitis C virus (HCV) protease (NS3/4A) inhibitor, which was approved and marketed in China since 2018 to treat chronic hepatitis C patients.METHODS:
This is an open-label, single arm study evaluating the effects of danoprevir boosted by ritonavir on treatment naïve and experienced COVID-19 patients for the first time. Patients received danoprevir boosted by ritonavir (100âmg/100âmg, twice per day). The primary endpoint was the rate of composite adverse outcomes and efficacy was also evaluated.RESULTS:
The data showed that danoprevir boosted by ritonavir is safe and well tolerated in all patients. No patient had composite adverse outcomes during this study. After initiation of danoprevir/ritonavir treatment, the first negative reverse real-time PCR (RT-PCR) test occurred at a median of 2 days, ranging from 1 to 8 days, and the obvious absorption in CT scans occurred at a median 3 days, ranging from 2 to 4 days. After 4 to 12-day treatment of danoprevir boosted by ritonavir, all enrolled 11 patients were discharged from the hospital.CONCLUSION:
Our findings suggest that repurposing danoprevir for COVID-19 is a promising therapeutic option.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Sulfonamidas
/
Prolina
/
Ritonavir
/
Ciclopropanos
/
Lactamas Macrocíclicas
/
Isoindoles
/
Tratamiento Farmacológico de COVID-19
Límite:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Medicine (Baltimore)
Año:
2020
Tipo del documento:
Article